Target intelligence / Profile preview

Leucine-rich repeat, immunoglobulin-like and transmembrane domains 1 (LRIT1)

Target
LRIT1
Molecular classification
Cell adhesion molecule (synaptic adhesion-like protein), Immunoglobulin superfamily domain-containing protein, Fibronectin type III domain-containing protein, Transmembrane protein, Leucine-rich repeat (LRR) protein
01

Overview

LRIT1 (Leucine-rich repeat, immunoglobulin-like and transmembrane domains 1) is a transmembrane synaptic adhesion-like protein specifically enriched at retinal cone photoreceptor synapses. It contains leucine-rich repeat motifs, immunoglobulin-like domains, fibronectin type III domains, and a transmembrane region anchoring it at the synapse. LRIT1 is critical for normal cone synaptic communication, enabling dynamic scaling of photoreceptor response to varying light conditions and maintaining visual acuity. LRIT1 forms a molecular complex with the glutamate receptor mGluR6 on ON-bipolar cells and the photoreceptor scaffold protein Frmpd2, regulating synaptic architecture and functional connectivity. Knockout or deficiency of LRIT1 in mice leads to abnormal synaptic signaling and impaired adaptation in vision, indicating its essential role in retinal function, but it is not a direct therapeutic drug target.

Other names
LRRC21FIGLER9Photoreceptor-associated LRR superfamily proteinRetina-specific protein PALfibronectin type III, immunoglobulin and leucine rich repeat domains 9PALDKFZP434K091
02

Mechanism of action

None known (no current drugs or agents act mechanistically through LRIT1)

03

Biological functions

Synaptic signaling in the retinaPhototransductionVisual perception and adaptationSynapse formation/specification between cone photoreceptors and ON-bipolar cellsModulation of synaptic gain and adaptation to background light
04

Disease associations

Visual acuity impairment/retinal signaling deficits (mice)The family is broadly implicated in neurodegenerative and immune-related conditions, but LRIT1 specifically is primarily linked to retinal dysfunction
05

Safety considerations

None specific. There are no documented therapeutic safety concerns, as LRIT1 is not a drug target. Loss in animal models leads to visual signaling impairment but does not affect retinal structure or viability
06

Interacting drugs

None known
07

Biomarkers

None established. LRIT1 is not currently used as a biomarker for patient selection or therapeutic efficacy

Beyond the preview

Go deeper on Leucine-rich repeat, immunoglobulin-like and transmembrane domains 1 (LRIT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leucine-rich repeat, immunoglobulin-like and transmembrane domains 1 (LRIT1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call